MedPath

Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-

QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase 3
Recruiting
Conditions
Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer
Interventions
Drug: QL1706
Drug: Gemcitabine
Drug: Cisplatin
Radiation: Intensity-modulated radiotherapy
First Posted Date
2024-12-27
Last Posted Date
2024-12-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
580
Registration Number
NCT06749899

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Phase 2
Not yet recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
24
Registration Number
NCT06745882
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1
Not yet recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Radiation: Low-dose radiotherapy
Drug: Tifcemalimab injection
Drug: Toripalimab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
First Posted Date
2024-12-13
Last Posted Date
2024-12-27
Lead Sponsor
Sichuan University
Target Recruit Count
12
Registration Number
NCT06732258

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2
Recruiting
Conditions
HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma
Interventions
First Posted Date
2024-12-12
Last Posted Date
2024-12-31
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
110
Registration Number
NCT06730373
Locations
🇨🇳

Shandong Univerisity Qilu Hospital, Jinan, Shandong, China

🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Jinan Third People's Hospital, Jinan, Shandong, China

and more 17 locations

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Phase 2
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: Tislelizumab-jsgr
Drug: Cisplatin
Drug: Albumin-Bound Paclitaxel
Radiation: Radiotherapy
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
50
Registration Number
NCT06725498
Locations
🇨🇳

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
Advanced and/or Metastatic Solid Tumors
Interventions
First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
InSilico Medicine Hong Kong Limited
Target Recruit Count
159
Registration Number
NCT06724042

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Esophageal Cancer
Interventions
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
112
Registration Number
NCT06718205
Locations
🇨🇳

Feng Wang, Zhengzhou, Henan, China

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2
Recruiting
Conditions
Advanced Biliary Tract Cancer
Interventions
First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Dai, Guanghai
Target Recruit Count
35
Registration Number
NCT06708858
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Advanced and Metastatic NSCLC
Interventions
First Posted Date
2024-11-26
Last Posted Date
2024-12-16
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
430
Registration Number
NCT06704620
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Phase 3
Not yet recruiting
Conditions
Oropharynx Cancer
Larynx Cancer
Hypopharynx Cancer
Primary Head and Neck Tumor
Interventions
Radiation: Standard radiotherapy
Drug: Vesanoid
Drug: Cisplatin
Radiation: Tailored radiotherapy
Drug: Cetuximab
First Posted Date
2024-11-26
Last Posted Date
2024-11-26
Lead Sponsor
Centre Leon Berard
Target Recruit Count
460
Registration Number
NCT06706401
Locations
🇫🇷

Centre Léon Bérard, Lyon, France

© Copyright 2025. All Rights Reserved by MedPath